Fractyl Health, Inc. announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. Mr. Conaway currently serves as President of U.S. Sales in the Cardiology Group at Boston Scientific Corporation and as Chairman of Close the Gap, the Boston Scientific Health Equity initiative.

His leadership roles have cemented his reputation as a driving force in the medical device sector. Mr. Conaway's expertise is expected to play a key role in Fractyl Health's ongoing efforts to complete its pivotal clinical studies in T2D and weight loss maintenance.